| Inhibitors of phosphatases -> Monitor Keywords |
|
Inhibitors of phosphatasesInhibitors of phosphatases description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20090060968, Inhibitors of phosphatases. Brief Patent Description - Full Patent Description - Patent Application Claims The present application claims the benefit of U.S. provisional application 60/437,567, filed Dec. 31, 2002, the entire disclosure whereof is incorporated herein by reference. TECHNICAL FIELD OF THE INVENTIONThe present invention relates to compounds that inhibit phosphatases, compositions thereof, and methods of using those compounds and compositions for treating diseases. BACKGROUND OF THE INVENTIONMany biologically important functions are regulated by the transfer of a phosphate group. Often, the active or inactive form of a compound is determined by the presence or absence of a phosphate group bound to that compound. Accordingly, many biological enzymes are involved in regulating this phosphate group transfer. For example, kinase enzymes catalyze transfer of a phosphate group from a nucleoside triphosphate to a protein receptor. In contrast, phosphatase enzymes remove a phosphate group from a substrate by hydrolysis. SHP-2 (src homology 2-containing protein tyrosine phosphatase) is a 68 kDa phosphatase protein and is also known as SHPTP2, Syp, PTP1D and PTP2C. Lu et al., Molecular Cell (2001) 8, 759. The enzyme is expressed in the cytoplasm of every tissue. SHP-2 is an important signaling enzyme, and the biological functions of SHP-2 have been extensively reviewed. Feng, Exp. Cell Res. (1999) 253, 45; Neel and Tonks, Curr. Opin. Cell Biol. (1997) 9, 193; Tonks, Adv. Pharmacol. (1996) 36, 91. The enzyme is activated through interactions with a variety of ligands including growth factors, cytokine receptor tyrosine kinases, and adhesion molecules and is most notably recognized as a positive regulator of cell proliferation. SHP-2 also plays an important function in immune signaling. Huyer and Alexander, Curr. Biol. (1999) 9, R129; Cohen et al., Cell (1995) 80, 237. The SHP-2 enzyme is required for activation of the Ras-MAP kinase cascade, although its precise role in the pathway is unclear. Van Vactor et al., Curr. Opin. Genet. Dev. (1998) 8, 112. SHP-2 has recently been identified as an intracellular target of Helicobacter pylori. Higashi et al., Science (2002) 295, 683. Due to the critical role SHP-2 plays in various biological pathways, development of inhibitors against the enzyme would provide useful treatments for cancer and other autoimmune diseases. Development of new chemical entities that modulate phosphatase enzymes such as SHP-2 would be an important advance and could lead to the development of novel treatments for diseases in which phosphatase enzymes play a critical role. The development of phosphatase modulators is an active area of research and has been extensively reviewed. Ripka, Annual Rev. Med. Chem. 2000, 35, Chapter 21 and references cited therein. More recent work has focused on the development of new heterocyclic groups that can mimic a phosphate moiety, i.e. the development of phosphate isosteres. A successful phosphate isostere will ideally be both nonhydrolyzable and bioavailable. Successful phosphate mimicry will also depend on the shape and ionization state of the mimic. Examples of new heterocyclic groups designed to mimic a phosphate moiety include tetronic acid derivatives investigated against Cdc25b, Sodeoka et al., J. Med. Chem. (2001) 44(20), 3216, and the azoledinedione class of inhibitors that have been investigated against protein tyrosine phosphatase 1B (PTB1B). Malamas et al., J. Med. Chem. (2000) 43, 995. However, the efficacy of these mimics is still being investigated. There is still a great need to develop potent modulators of phosphatase enzymes and other enzymes that are involved in regulating the transfer of a phosphate group. SUMMARY OF THE INVENTIONThe present invention relates to compounds of formula (I):
wherein: ring A is an aryl or heteroaryl ring; Ra is —COOH, a salt or an ester thereof, or a bioisostere thereof; n is 1-3; R1 is H, hydroxyaliphatic, aminoaliphatic, aliphatic-COOH, aliphatic-CONH2, or arylaliphatic; Continue reading about Inhibitors of phosphatases... Full patent description for Inhibitors of phosphatases Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Inhibitors of phosphatases patent application. ### 1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Inhibitors of phosphatases or other areas of interest. ### Previous Patent Application: Antimicrobial fiber and method for producing the same thereof Next Patent Application: Porous biodegradable polymeric materials for cell transplantation Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Inhibitors of phosphatases patent info. IP-related news and info Results in 2.0755 seconds Other interesting Feshpatents.com categories: Accenture , Agouron Pharmaceuticals , Amgen , AT&T , Bausch & Lomb , Callaway Golf orig |
* Protect your Inventions * US Patent Office filing
PATENT INFO |
|